AbCellera Biologics (ABCL) Income towards Parent Company: 2020-2023
Historic Income towards Parent Company for AbCellera Biologics (ABCL) over the last 4 years, with Dec 2023 value amounting to -$47.1 million.
- AbCellera Biologics' Income towards Parent Company fell 57.73% to -$47.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$146.4 million, marking a year-over-year decrease of 192.35%. This contributed to the annual value of -$162.9 million for FY2024, which is 11.24% down from last year.
- Latest data reveals that AbCellera Biologics reported Income towards Parent Company of -$47.1 million as of Q4 2023, which was down 64.80% from -$28.6 million recorded in Q3 2023.
- In the past 5 years, AbCellera Biologics' Income towards Parent Company ranged from a high of $168.6 million in Q1 2022 and a low of -$47.1 million during Q4 2023.
- Moreover, its 3-year median value for Income towards Parent Company was -$14.1 million (2021), whereas its average is $13.8 million.
- Over the last 5 years, AbCellera Biologics' Income towards Parent Company had its largest YoY gain of 5,700.62% in 2021, and its largest YoY loss of 693.91% in 2021.
- AbCellera Biologics' Income towards Parent Company (Quarterly) stood at $161.2 million in 2020, then plummeted by 62.80% to $59.9 million in 2021, then crashed by 149.86% to -$29.9 million in 2022, then tumbled by 57.73% to -$47.1 million in 2023.
- Its Income towards Parent Company was -$47.1 million in Q4 2023, compared to -$28.6 million in Q3 2023 and -$30.5 million in Q2 2023.